• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Relugolix combination therapy led to reduction in uterine fibroid symptoms

byConstance Wu
March 5, 2021
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Once-daily relugolix combination therapy resulted in a significant reduction in heavy menstrual bleeding compared with placebo in women with uterine fibroids.

2. The combination therapy preserved bone mineral density and minimized the incidence of hot flashes.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Uterine fibroids can be associated with heavy menstrual bleeding, anemia, and pain. First-line treatment with contraceptives has low-quality evidence for their use. Relugolix is an oral GnRH antagonist suitable for daily use. This study reported the results of two phases 3 trials, which assessed the efficacy and safety of once-daily relugolix combination therapy in women with fibroid-associated heavy menstrual bleeding. Relugolix combination therapy resulted in a significant reduction in fibroid-associated bleeding with the resolution of anemia and an improvement in pain and discomfort. Preservation of bone mineral density and minimized incidence of hot flashes were also noted in comparison to relugolix monotherapy. Limitations include limited generalizability given many women were excluded due to stringent criteria. The trial regimen was also restricted to six months, therefore long-term effects remain to be assessed. Nonetheless, this study’s results are significant, and its findings highlight evidence of relugolix combination therapy decreased fibroid-associated bleeding and improved patient comfort.

Click to read the study in NEJM

Relevant Reading: Oral gonadotropin-releasing hormone antagonist relugolix compared with leuprorelin injections for uterine leiomyomas: a randomized controlled trial.

In-Depth [randomized controlled trial]: This study reported the results of two replicate, randomized controlled phase 3 trials. The trials enrolled 770 women from North America, South America, Africa, and Europe between both trials. Women between the ages of 18 to 50 years old, known diagnoses of fibroids, and who had heavy menstrual bleeding were included in the study. Participants on hormonal therapy or with other causes for menstrual bleeding were excluded from the study. Participants were randomized to the relugolix combination group or the placebo group. The primary endpoint was trial response defined as blood loss less than 80 mL and a reduction of at least 50% from baseline menstrual blood loss. Overall, 73% of participants in the first trial and 71% in the second trial achieved the primary endpoint in the treatment group, compared with 19% and 15% in the placebo groups, respectively (P < 0.001 for each comparison). More than 50% of participants with anemia in the treatment group had an increase of more than 2 g/dL in hemoglobin levels compared to placebo (first trial, P = 0.04; second trial, P < 0.001). Percent changes in bone mineral density from baseline were similar between the relugolix combination therapy group and placebo group. Taken together, relugolix combination therapy was shown to decrease menstrual bleeding and improve fibroid-related symptoms in premenopausal women.

RELATED REPORTS

Relugolix combination therapy is efficacious for endometriosis-associated pain

Relugolix combination therapy led to reduction in uterine fibroid symptoms

#VisualAbstract: Myomectomy associated with better fibroid-related quality of life versus uterine-artery embolization

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Fibroidsrelugolixuterine fibroidsuterus
Previous Post

Cabozantinib improves progression-free survival in patients with metastatic papillary renal cell carcinoma

Next Post

#VisualAbstract OAsIS: Ibrutinib, obinutuzumab, and venetoclax was well-tolerated and showed high response rates in both untreated and relapsed mantle cell lymphoma

RelatedReports

Chronic Disease

Relugolix combination therapy is efficacious for endometriosis-associated pain

June 30, 2022
Simvastatin associated with slowed fibroid growth in mice
Obstetrics

Relugolix combination therapy led to reduction in uterine fibroid symptoms

February 27, 2021
#VisualAbstract: Myomectomy associated with better fibroid-related quality of life versus uterine-artery embolization
StudyGraphics

#VisualAbstract: Myomectomy associated with better fibroid-related quality of life versus uterine-artery embolization

August 5, 2020
Testosterone replacement in male cancer survivors helps improve body composition
Chronic Disease

Relugolix treatment significantly decreases testosterone levels in advanced prostate cancer

June 7, 2020
Next Post
#VisualAbstract OAsIS: Ibrutinib, obinutuzumab, and venetoclax was well-tolerated and showed high response rates in both untreated and relapsed mantle cell lymphoma

#VisualAbstract OAsIS: Ibrutinib, obinutuzumab, and venetoclax was well-tolerated and showed high response rates in both untreated and relapsed mantle cell lymphoma

Many new pediatric asthma cases attributable to obesity

Food security status lower effectiveness of lifestyle-based weight loss approaches

Thrombophilia-associated stillbirth risk appears limited to factor V Leiden

2 Minute Medicine Rewind March 8, 2021

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Stereotactic body radiotherapy as a state of the art treatment option in inoperable non-small cell lung cancer [Classics Series]
  • Health system-based care associated with better treatment use and high rates of tobacco abstinence at 3 months post-discharge in hospitalized smokers
  • APOEε4 genotype may increase risk of chronic traumatic encephalopathy following repetitive head impact
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.